Lasofoxifene
ER+, ESR1-Mutant Metastatic Breast Cancer
Phase 3Active (Licensed)
Key Facts
Indication
ER+, ESR1-Mutant Metastatic Breast Cancer
Phase
Phase 3
Status
Active (Licensed)
Company
About LeonaBio
LeonaBio, a rebranded entity from Athira Pharma, is a clinical-stage biotech focused on oncology and neurology. Its strategy pivoted decisively in late 2025 with the in-licensing of the Phase 3 breast cancer candidate lasofoxifene and a financing package of up to $236 million. The company's mission is to advance targeted, small molecule therapeutics for specific, underserved patient populations, leveraging differentiated mechanisms of action to address critical resistance pathways in cancer and neurodegeneration.
View full company profile